A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: Not specified

Inclusion Criteria

Inclusion Criteria: 1. Male or female, age =18 years at the time of signing informed consent. 2. Body mass index (BMI) =28 kg/m^2 at screening, OR BMI =24 kg/m^2 at screening with the presence of at least one of the following weight-related complications: - Hypertension (defined as repeated, i.e. at least 3 measurements in resting condition, systolic blood pressure (SBP) values of =140 mmHg and/or diastolic blood pressure (DBP) values of =90 mmHg in the absence of anti-hypertensive treatment, or intake of at least 1 anti-hypertensive drug to maintain a normotensive blood pressure) - Dyslipidaemia (defined as at least 1 lipid-lowering treatment required to maintain normal blood lipid levels, or low density lipoprotein (LDL) =160 mg/dL (=4.1 mmol/L), or triglycerides =150 mg/dL (=1.7 mmol/L), or high density lipoprotein (HDL) <40 mg/dL (<1.0 mmol/L) for men or HDL<50 mg/dL (<1.3 mmol/L) for women) - Obstructive sleep apnoea - Cardiovascular disease (CVD) (e.g. heart failure (HF) with New York Heart Association (NYHA) functional class II-III, history of ischaemic or haemorrhagic stroke or cerebrovascular revascularisation procedure [e.g. carotid endarterectomy and/or stent], myocardial infarction (MI), coronary artery disease, or peripheral vascular disease) - Type 2 diabetes mellitus (T2DM) diagnosed at least 180 days prior to screening (glycosylated haemoglobin A1c (HbA1c) =6.5% (48 mmol/mol) and <10% (86 mmol/mol), and fasting plasma glucose (FPG) =11.1 mmol/L measured by the central laboratory at screening --- Currently treated with either: diet and exercise alone or stable treatment (for at least 3 months prior to screening) with metformin, sodium-glucose cotransporter-2 inhibitor (SGLT2i) inhibitor, acarbose, sulfonylurea, or glitazone as single agent therapy, or up to 3 anti-hyperglycaemia medications (metformin, SGLT2i, acarbose, sulfonylurea, or glitazone) according to local label - Non-alcoholic steatohepatitis (NASH), as assessed in medical records by histological liver assessment (within the last 6 months) 3. History of at least one self-reported unsuccessful dietary effort to lose body weight 4. Signed and dated written informed consent in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial 5. Woman of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of their use will be provided in the participant information. Further inclusion criteria apply. Exclusion Criteria: (A) Obesity: 1. Body weight change (self-reported) >5% within 3 months before screening. 2. Treatment with any medication for the indication obesity within 3 months before screening. 3. Previous or planned (during the trial period) treatment for obesity with surgery or a weight loss device, or prior surgery of the GI tract that could interfere with body weight The following are allowed: (1) liposuction and/or abdominoplasty, if performed >1 year before screening, (2) lap banding, if the band has been removed >1 year before screening, (3) intragastric balloon, if the balloon has been removed >1 year before screening, (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed >1 year before screening, (5) appendectomy, (6) simple hernia repair, or (7) cholecystectomy 4. Have obesity induced by other endocrinologic disorders (for example, Cushing Syndrome) or diagnosed monogenetic or syndromic forms of obesity (for example, melanocortin 4 receptor deficiency, leptin deficiency, or Prader Willi Syndrome) (B) Diabetes-related for participants with T2DM: 5. Treatment with any medication for the indication of T2DM other than stated in the inclusion criteria within 3 months before screening (i.e. insulin, amylin analogues, glucagon-like peptide-1 receptor (GLP- 1R)) agonists, GLP-1R agonist/insulin/glucose-dependent insulinotropic polypeptide (GIP) combinations, and dipeptidyl peptidase 4 inhibitor (DPP-4i)) 6. New initiation of any other glucose-lowering investigational drug within 3 months prior to screening for this trial 7. Uncontrolled and potentially unstable diabetic retinopathy or maculopathy, verified by an eye examination within 3 months prior to screening or in the period between screening and randomisation Further exclusion criteria apply.

Exclusion Criteria

Not provided

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Achievement of body weight reduction =5% (yes/no) from baseline to Week 52;Percentage change in body weight from baseline to Week 52

Secondary Outcome Measures

Name	Time	Method

Related Trials

A study of anifrolumab in children and adolescents (5 to < 18 years old) with moderate to severe lupus to find the appropriate anifrolumab dose for those participants and to confirm anifrolumab is safe and works in this populatio

Phase 1

AstraZeneca AB

Updated 8/21/2024

To Study the Efficacy, Safety and Immunogenicity of Aflibercept in Patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD)

Phase 3

Zydus Lifesciences Limited

Updated 5/27/2024

A Clinical Study that will measure how well SEP-363856 works and how safe it is in adults with Generalized Anxiety Disorder

RecruitingPhase 1

Sunovion Pharmaceuticals Inc.

Updated 8/21/2024

Phase III clinical study to compare safety and efficacy of 2 Dosage of Telmisartan and Azelnidipine when compared to Telmisartan and Almlodipine in Patients with Stage II Hypertensio

CompletedPhase 3

Synokem Pharmaceuticals Ltd

Updated 11/24/2021

A clinical trial to study the effects of combination of Rosuvastatin plus Teneligliptin Tablets in diabetic patients with high lipid levels.

CompletedPhase 3

Synokem Pharmaceuticals Ltd

Updated 11/24/2021

A study to evaluate the effect and safety of linagliptin 5 mg administered in combination with empagliflozin 10 mg or 25 mg in patients with type 2 diabetes mellitus whose glucose levels have not been controlled after 16 weeks of treatment with empagliflozin 10 mg or 25 mg and metformin.

Boehringer Ingelheim España, S.A

Updated 7/10/2015

A study to evaluate the effect and safety of linagliptin 5 mg administered in combination with empagliflozin 10 mg or 25 mg in patients with type 2 diabetes mellitus whose glucose levels have not been controlled after 16 weeks of treatment with empagliflozin 10 mg or 25 mg and metformin.

BOEHRINGER ING.

Updated 10/19/2015

A study to evaluate the effect and safety of linagliptin 5 mg administered in combination with empagliflozin 10 mg or 25 mg in patients with type 2 diabetes mellitus whose glucose levels have not been controlled after 16 weeks of treatment with empagliflozin 10 mg or 25 mg and metformin.

nilfarma, Lda.

Updated 10/19/2015

A study to evaluate the effect and safety of linagliptin 5 mg administered in combination with empagliflozin 10 mg or 25 mg in patients with type 2 diabetes mellitus whose glucose levels have not been controlled after 16 weeks of treatment with empagliflozin 10 mg or 25 mg and metformin.

Boehringer Ingelheim Pharma GmbH & Co. KG

Updated 11/23/2015

Clinical Study to see effect and safety of linagliptin 5mg compared to inactive drug,given as oral fixed dose combination with empagliflozin 10mg or 25mg for 24 wks,in pts with type 2 diabetes mellitus and uncontrolled glucose levels in bld after 16 wks of trtm with empa 10mg or 25mg & metformin.

Phase 3

BoehringerIngelheim India Pvt Ltd

Updated 11/24/2021

A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

Recruitment & Eligibility

Study & Design

Related Trials

A study of anifrolumab in children and adolescents (5 to < 18 years old) with moderate to severe lupus to find the appropriate anifrolumab dose for those participants and to confirm anifrolumab is safe and works in this populatio

To Study the Efficacy, Safety and Immunogenicity of Aflibercept in Patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD)

A Clinical Study that will measure how well SEP-363856 works and how safe it is in adults with Generalized Anxiety Disorder

Phase III clinical study to compare safety and efficacy of 2 Dosage of Telmisartan and Azelnidipine when compared to Telmisartan and Almlodipine in Patients with Stage II Hypertensio

A clinical trial to study the effects of combination of Rosuvastatin plus Teneligliptin Tablets in diabetic patients with high lipid levels.

A study to evaluate the effect and safety of linagliptin 5 mg administered in combination with empagliflozin 10 mg or 25 mg in patients with type 2 diabetes mellitus whose glucose levels have not been controlled after 16 weeks of treatment with empagliflozin 10 mg or 25 mg and metformin.

A study to evaluate the effect and safety of linagliptin 5 mg administered in combination with empagliflozin 10 mg or 25 mg in patients with type 2 diabetes mellitus whose glucose levels have not been controlled after 16 weeks of treatment with empagliflozin 10 mg or 25 mg and metformin.

A study to evaluate the effect and safety of linagliptin 5 mg administered in combination with empagliflozin 10 mg or 25 mg in patients with type 2 diabetes mellitus whose glucose levels have not been controlled after 16 weeks of treatment with empagliflozin 10 mg or 25 mg and metformin.

A study to evaluate the effect and safety of linagliptin 5 mg administered in combination with empagliflozin 10 mg or 25 mg in patients with type 2 diabetes mellitus whose glucose levels have not been controlled after 16 weeks of treatment with empagliflozin 10 mg or 25 mg and metformin.

Clinical Study to see effect and safety of linagliptin 5mg compared to inactive drug,given as oral fixed dose combination with empagliflozin 10mg or 25mg for 24 wks,in pts with type 2 diabetes mellitus and uncontrolled glucose levels in bld after 16 wks of trtm with empa 10mg or 25mg & metformin.

Clinical Trial Alerts

Clinical Trial Alerts